Divi's Laboratories Limited (DIVISLAB) — Announcement Announcement
📢 Key Event
Divi's Laboratories received Draft Assessment Order proposing ₹570.51 crores in income tax additions for FY2022-23.
🔄 What Changed
Draft Order issued March 20, 2026 for assessment year 2023-24; transfer pricing and corporate tax adjustments proposed vs. returned income
🔮 What's Next
Company will file appeal against Draft Order within stipulated time period.
💡 Investor Takeaway
Shareholders face uncertainty regarding a material ₹570.51 crores tax adjustment and pending penalty proceedings, with final impact dependent on appeal success.
⚠️ Risks
Penalty proceedings initiated for alleged income underreporting; potential significant tax liability and reputational impact pending appeal outcome
Divi's Laboratories received a Draft Assessment Order from the Income Tax Authority for FY2022-23 proposing **₹570.51 crores** in additions/disallowances related to transfer pricing adjustments on domestic transactions and corporate tax adjustments. The company faces potential additional income tax liability and separate penalty proceedings under Section 270A for alleged income underreporting. Management plans to evaluate and file an appeal within the stipulated timeframe.
📄 View Original Announcement (PDF)
About Divi's Laboratories Limited (DIVISLAB)
Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE
Market Cap: ₹1,79,470.03 Cr
P/E: 72.4
ROE: 16.6%
ROCE: 22.1%
Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.